FMP
FSD Pharma Inc.
HUGE
NASDAQ
Inactive Equity
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
0.0899 USD
-0.0101 (-11.23%)
About
ceo
Mr. Zeeshan Saeed
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.fsdpharma.comexchange
NASDAQ
Description
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
CIK
0001771885
ISIN
CA35954B4047
CUSIP
35954B206
Address
199 Bay Street
Phone
416 854 8884
Country
CA
Employee
17
IPO Date
Jun 8, 2018
Key Executives
